Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Nakajima, W ^a   Hicks, M A ^a   Tanaka, N ^b   Krystal, G W ^c   Harada, H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABT 737; lung cancer; MCL 1; Noxa; protein stability

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; PROTEASOME; PROTEIN MCL 1; PROTEIN NOXA;

ARTICLE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; REGULATORY MECHANISM; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICE, KNOCKOUT; MITOCHONDRIA; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PHOSPHORYLATION; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; TRANSFECTION; UBIQUITINATION;

EID: 84896744746     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.6     Document Type: Article

References (31)

1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366: 1385-1396.
2. Aisner J. Extensive-disease small-cell lung cancer: The thrill of victory; the agony of defeat. J Clin Oncol 1996; 14: 658-665.
3. Johnson DH, Carbone DP. Increased dose-intensity in small-cell lung cancer: A failed strategy? J Clin Oncol 1999; 17: 2297-2299.
4. Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 1999; 17: 2309-2315.
5. Kelly K, Lovato L, Bunn Jr. PA, Livingston RB, Zangmeister J, Taylor SA et al. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. Clin Cancer Res 2001; 7: 2325-2329.
6. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
7. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
8. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145: 1036-1040.
9. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6-8.
10. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
11. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176-1183.
12. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
13. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008; 14: 3268-3277.
14. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
15. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-185.
16. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. 'Seed' analysis of off-Target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979.
17. Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009; 8: 883-892.
18. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
19. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
20. Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R et al. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 2010; 95: 1510-1518.
21. Seo YW, Shin JN, Ko KH, Cha JH, Park JY, Lee BR et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J Biol Chem 2003; 278: 48292-48299.
22. Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T. Phosphate-binding tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics 2006; 5: 749-757.
23. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
24. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2: 239-244.
25. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67: 2908-2911.
26. Kuroda J, Taniwaki M. Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol 2009; 71: 89-101.
27. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012; 30: 3127-3135.
28. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
29. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR et al. NCINavy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 1996; 24: 32-91.
30. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
31. Craxton A, Butterworth M, Harper N, Fairall L, Schwabe J, Ciechanover A et al. NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitinindependent pathway that is blocked by MCL-1. Cell Death Differ 2012; 19: 1424-1434.